Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03423173 · ClinicalTrials.gov registry record · Phase 3
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 923
- Enrollment target
NCT03423173 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 923 participants.
The verdict
NCT03423173, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 923 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for dengue.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TAK-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 923 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03423173
The ClinicalTrials.gov registry entry for NCT03423173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 923 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03423173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03423173 about?
NCT03423173 is a clinical study titled "Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue". The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for dengue.
What is the current status of trial NCT03423173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 923 participants. The study started on 2018-02-12. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT03423173?
The interventions under investigation include: Placebo (BIOLOGICAL), TAK-003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03423173?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.